Claims for Patent: 11,793,805

Summary for Patent: 11,793,805

Title:	Methods for treating antipsychotic-induced weight gain
Abstract:	The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s):	Daniel R. Deaver, Mark Todtenkopf
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US17/505,896
Patent Claims:	1. A method of treating schizophrenia, in a patient in need thereof, where the patient has previously experienced significant weight gain induced by olanzapine treatment alone, comprising administering to the patient a daily dose of a pharmaceutical composition comprising: olanzapine or a pharmaceutically acceptable salt thereof; and 10 mg of a compound having the structure: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the patient on olanzapine treatment alone previously gained at least 2% of their initial body weight after ten weeks of olanzapine administration. 3. The method of claim 1, wherein the patient on olanzapine treatment alone previously gained at least 5% of their initial body weight after ten weeks on olanzapine administration. 4. The method of claim 1, wherein the pharmaceutical composition is a tablet. 5. The method of claim 1, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 6. The method of claim 1, wherein the weight gain induced by olanzapine treatment alone is mitigated by the co-administration of a pharmaceutical composition comprising: olanzapine or a pharmaceutically acceptable salt thereof; and 10 mg of a compound having the structure: or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 8. A method of treating schizophrenia, in a patient in need thereof, wherein a significant weight gain induced by olanzapine treatment alone is mitigated by the co-administration of a daily dose of a pharmaceutical composition comprising: olanzapine or a pharmaceutically acceptable salt thereof; and 10 mg of a compound having the structure: or a pharmaceutically acceptable salt thereof. 9. The method of claim 8, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.